Coagulation profile of human COVID-19 convalescent plasma

Klompas, Allan M.; Helmond, Noud van; Juskewitch, Justin E.; Pruthi, Rajiv K.; Sexton, Matthew A.; Soto, Juan C. Diaz; Klassen, Stephen A.; Senese, Katherine A.; Buskirk, Camille M. van; Winters, Jeffrey L.; Stubbs, James R.; Hammel, Scott A.; Joyner, Michael J.; Senefeld, Jonathon W.

doi:10.1038/s41598-021-04670-1

Cited by 7 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are in agreement with a recent study showing no differences in CTs and coagulation factor assays, except for protein C antigen between CCP from adults who had recovered from COVID-19 and standard FFP from healthy adult volunteers. 38 Some variations in hemostasis between FFP, FDP, and the healthy control could be due to plasma sources and preparations (pooled FFP versus freshly prepared plasma from a healthy volunteer), 39 storage time, and condition. 40 Frozen storage time could affect the coagulation tests and factor activities of plasma even at À80°C.…”

Section: Discussionmentioning

confidence: 99%

Freeze‐dried plasma: From damage control resuscitation to coronavirus disease 2019 therapy

et al. 2022

View full text Add to dashboard Cite

Background: Freeze-dried plasma (FDP) is a promising blood component for prehospital resuscitation given its logistic advantages over fresh frozen plasma (FFP). COVID-19 convalescent (CC) plasma has been used to treat coronavirus disease 2019 (COVID-19) patients, and its corresponding FDP has potential use during future pandemics. Therefore, we conducted the study to determine if the hemostatic and immunological properties of plasma can be retained after lyophilization.Study design and methods: Hemostatic tests were conducted with Rotational Thromboelastometry (ROTEM) and a Stago analyzer. Anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG (Immunoglobulin G) and neutralizing activity were analyzed using Meso Scale Diagnostics immunoassay kits.Results: There were no differences in ROTEM parameters and Stago measurements for prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen and D-dimer concentrations, and antithrombin, factor V, VIII, and protein S activities between FFP and FDP for either pre-COVID-19 or CC samples. Differences were observed in INTEM clotting time and PT and PTT when comparing reconstituted FDP stored at 4°C for 24 h or room temperature for 4 h to healthy control. Both CC-FFP and CC-FDP showed two orders of magnitude higher concentrations of IgG antibodies against SARS-CoV-2 antigens than pre-COVID-19-FFP and pre-COVID-19-FDP and healthy control. Similarly, the CC samples showed approximately 4-fold higher %-inhibition of receptor binding than the pre-COVID-19 samples. There were no differences in either the antibody levels or neutralization activity between CC-FFP and CC-FDP.Discussion: We demonstrated that FDP and CC-FDP retained the same hemostatic and antibody functional activities relative to their initial plasma sources, supporting clinical evaluation of their benefits in severe trauma and COVID-19 patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Freeze‐dried plasma: From damage control resuscitation to coronavirus disease 2019 therapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Nevertheless, these reports concluded that it is unlikely that this decrease has any clinical impact. By contrast, Klompas and colleagues recently demonstrated that the loss of coagulation factor activity in pathogen-reduced COVID-19 convalescent plasma had a clinical impact associated with the pathogen reduction process ( Klompas et al, 2022 ). Moreover, in agreement with our results, they demonstrated an increase in APTT and TT, suggesting that a slight prolongation of coagulation times may occur due to the combined loss of activity of several coagulation factors ( Hornsey et al, 2009 ; Klompas et al, 2022 ).…”

Section: Discussionmentioning

confidence: 99%

“…By contrast, Klompas and colleagues recently demonstrated that the loss of coagulation factor activity in pathogen-reduced COVID-19 convalescent plasma had a clinical impact associated with the pathogen reduction process ( Klompas et al, 2022 ). Moreover, in agreement with our results, they demonstrated an increase in APTT and TT, suggesting that a slight prolongation of coagulation times may occur due to the combined loss of activity of several coagulation factors ( Hornsey et al, 2009 ; Klompas et al, 2022 ). In line with these studies, we also found a significant reduction of functional protein C and FV, FX, and FXI levels, and a slight decrease in FVIII, FXIII and fibrinogen after inactivation.…”

Section: Discussionmentioning

confidence: 99%

Inactivation of human plasma alters the structure and biomechanical properties of engineered tissues

Rosell‐Valle¹,

Martín-López

Campos

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Fibrin is widely used for tissue engineering applications. The use of blood derivatives, however, carries a high risk of transmission of infectious agents, necessitating the application of pathogen reduction technology (PRT). The impact of this process on the structural and biomechanical properties of the final products is unknown. We used normal plasma (PLc) and plasma inactivated by riboflavin and ultraviolet light exposure (PLi) to manufacture nanostructured cellularized fibrin-agarose hydrogels (NFAHs), and then compared their structural and biomechanical properties. We also measured functional protein C, prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and coagulation factors [fibrinogen, Factor (F) V, FVIII, FX, FXI, FXIII] in plasma samples before and after inactivation. The use of PLi to manufacture cellularized NFAHs increased the interfibrillar spacing and modified their biomechanical properties as compared with cellularized NFAH manufactured with PLc. PLi was also associated with a significant reduction in functional protein C, FV, FX, and FXI, and an increase in the international normalized ratio (derived from the PT), APTT, and TT. Our findings demonstrate that the use of PRT for fibrin-agarose bioartificial tissue manufacturing does not adequately preserve the structural and biomechanical properties of the product. Further investigations into PRT-induced changes are warranted to determine the applications of NFAH manufactured with inactivated plasma as a medicinal product.

show abstract

“…76 Convalescent plasma treatment could be the solution for restoring the coagulation factor. 77 In a study conducted by Klompas et al 78 , low rates of thrombotic and thromboembolic events were found in COVID-19 patients, even in critically ill COVID-19 patients, who had convalescent plasma transfusion. 78 Convalescent plasma provides procoagulant and antifibrinolytic factors that could restore the endothelium glycocalyx and prevent vascular leakage.…”

Section: Restoration Of Coagulation Factormentioning

confidence: 97%

“…77 In a study conducted by Klompas et al 78 , low rates of thrombotic and thromboembolic events were found in COVID-19 patients, even in critically ill COVID-19 patients, who had convalescent plasma transfusion. 78 Convalescent plasma provides procoagulant and antifibrinolytic factors that could restore the endothelium glycocalyx and prevent vascular leakage. 77 Steric hindrance between receptor and ligand that provides by plasma and proteins in plasma have important role in fixing the endothelium glycocalyx.…”

Section: Restoration Of Coagulation Factormentioning

confidence: 97%

Effectiveness of convalescent plasma therapy for COVID-19 patients infected with variants of concerns

Kurniawati¹,

Putri²,

Widiatmaja³

et al. 2022

Anaesth. pain intensive care

View full text Add to dashboard Cite

COVID-19 cases in Indonesia seemed to be increasing by each passing day at the time of writing this review, more positive cases discovered than the recovered ones. With the highest rank within all ASEAN countries, and also a home of many variants of COVID-19, Indonesia had become a break off destination to others. Along with the problem associated with the pandemic, which all people had to face, the purpose of this review is to elaborate the use of convalescent plasma therapy on treatment against COVID-19, especially its different variants. We overview the evidence that we obtained from several databases using specific keywords. A large amount of evidence points out that the convalescent plasma therapy has shown a promising outcome against COVID-19 infection, as it did for infectious diseases. Although in COVID-19 variants of concern, convalescent plasma therapy showed a reduction in neutralization ~ 3-fold against P.1, and 7-13 folds against B.1.351 variant, it still can be used as a treatment for COVID-19 and its variants. Abbreviations: PPE - personal protective equipment; VoC - Variants of concern; VoI - Variants of interest; CPT - convalescent plasma therapy; RBD - receptor-binding domain; ARDS - Acute Respiratory Distress Syndrome; ICU - Intensive Care Unit; IQR - Interquartile Range; RCT - Randomized Clinical Trial; RT-PCR - Reverse Transcriptase-Polymerase Chain Reaction; NAbs - neutralizing antibodies Key words: Convalescent plasma therapy; COVID-19, Variants of Concern Citation: Kurniawati EM, Putri IS, Widiatmaja DM, Praba VM, Visuddho 2, Prameswari FU, Zahrani M, Putra FN, Nugraha D, Widiastara AA. Effectiveness of convalescent plasma therapy for COVID-19 patients infected with variants of concerns. Anaesth. pain intensive care 2022;26(4):535-545; DOI: 10.35975/apic.v26i4.1962 Received: July 31, 2021; Reviewed: May 17, 2022; Accepted: May 18, 2022

show abstract

Coagulation profile of human COVID-19 convalescent plasma

Cited by 7 publications

References 34 publications

Freeze‐dried plasma: From damage control resuscitation to coronavirus disease 2019 therapy

Freeze‐dried plasma: From damage control resuscitation to coronavirus disease 2019 therapy

Inactivation of human plasma alters the structure and biomechanical properties of engineered tissues

Effectiveness of convalescent plasma therapy for COVID-19 patients infected with variants of concerns

Contact Info

Product

Resources

About